Disease Information & Support


The Word:


Generic name Liposomal doxorubicin
Pronunciation Lip-SOH-mal dok-soh-ROO-bi-sin
Brand name(s), other common name(s) Doxil®
Drug type  Antitumor antibiotic
How the drug is given Intravenously (IV)

Liposomal doxorubicin is FDA approved for use in combination with bortezomib to treat patients with myeloma who have not previously received bortezomib and have received at least one prior therapy. See the FDA announcement about drug shortage of Doxil.

Side effects needing medical attention: Loss of appetite (or weight loss); nausea; vomiting; stomach pain; diarrhea; constipation; unusual tiredness or weakness; dizziness; hair loss; nosebleed; red or orange discoloration of urine; sores in the mouth and throat; tingling, burning, redness, swelling, peeling or flaking, blisters, or sores on the palms of the hands or soles of the feet; pain, itching, redness, swelling, blisters, or sores in the place where the medication was injected.


For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.

last updated on Monday, December 30, 2013